T2D • Non-Insulin-Dependent Diabetes • Adult-Onset Diabetes

Metabolic. Not the same disease as Type 1. Not always caused by lifestyle. Not always reversible.

Before you read further — Type 1 and Type 2 are different diseases

Type 1 and Type 2 diabetes share a name, a monitoring tool, and almost nothing else.

Type 2 involves insulin resistance — cells that gradually stop responding normally to insulin the body is still producing. The pancreas compensates by making more insulin. Eventually it cannot keep up. Blood glucose rises.

Type 1 is an autoimmune disease in which the immune system destroys the insulin-producing beta cells entirely. The pancreas stops making insulin. Insulin replacement is required for survival — full stop.

If you are looking for the Type 1 page, it is in the Metabolic & Genetic section of the Medical Library.

What it is

Type 2 diabetes is a metabolic condition characterized by insulin resistance — a state in which the body's cells no longer respond normally to insulin — combined with progressive decline in the pancreas's ability to compensate by producing more of it.

In a functioning system, insulin acts as a key that unlocks cells to allow glucose to enter from the bloodstream. In insulin resistance, the lock becomes less responsive. The pancreas notices glucose isn't clearing and produces more insulin to compensate. For a period — sometimes years or decades — this compensation keeps blood glucose in a manageable range. When the pancreas can no longer keep up with the demand, blood glucose rises into the diabetic range.

Type 2 affects an estimated 37 million Americans and accounts for approximately 90 to 95 percent of all diabetes diagnoses. It is the most common form of diabetes by a wide margin.

There is no cure in the conventional sense, though meaningful remission is achievable in some patients through significant dietary change, weight loss, and in some cases bariatric surgery. This is not the same as being cured — the underlying metabolic tendency remains, and remission requires sustained management.

What it is not

Type 2 diabetes is not:

• The same disease as Type 1 — the mechanism, the cause, and the management are fundamentally different

• Always caused by obesity or poor diet — genetics play a significant role, and Type 2 occurs in people across the full weight spectrum

• Always preventable — genetic predisposition is real and meaningful

• Always reversible — remission is possible for some patients, particularly with early intervention, but it is not guaranteed and it is not a cure

• A character failing — the cultural framing of Type 2 as a self-inflicted condition has caused significant harm and obscured the genetic and metabolic complexity of what is actually happening

Symptoms

Type 2 often develops gradually and silently. Many people are diagnosed incidentally on routine bloodwork before they notice any symptoms at all.

Common symptoms when present:

• Increased thirst and frequent urination

• Fatigue — cells not getting adequate glucose means inadequate energy

• Blurred vision

• Slow-healing wounds or frequent infections

• Darkened skin in body folds and creases — acanthosis nigricans, a marker of insulin resistance

• Numbness or tingling in hands or feet — peripheral neuropathy, typically a sign of longer-term uncontrolled glucose

The silent progression problem: Because Type 2 can be asymptomatic for years while damage accumulates, the standard recommendation is screening for adults over 35, or earlier with risk factors. Many people are diagnosed after complications — nerve damage, kidney disease, eye damage — have already begun. Early detection matters.

The metabolic cluster — Type 2 rarely travels alone

Type 2 diabetes is frequently one component of a larger metabolic picture. The cluster of conditions that appear together — elevated blood glucose, elevated triglycerides, low HDL cholesterol, high blood pressure, and excess abdominal weight — is formally called metabolic syndrome.

These findings share underlying mechanisms involving insulin resistance and altered fat metabolism. They tend to appear together, worsen together, and respond to intervention together.

Elevated triglycerides deserve specific attention on this page.

Elevated triglycerides in the context of Type 2 — or in the context of pre-diabetes, insulin resistance, or metabolic syndrome — are almost universally attributed to carbohydrate intake, dietary fat, or the metabolic consequences of insulin resistance itself. That attribution is often correct.

But there is another upstream cause that the standard diabetes workup is not designed to find.

HFI Triad note: Elevated triglycerides, NAFLD, and reactive hypoglycemia can each appear as standalone findings — but when they cluster together, especially alongside a history of aversion to sweet foods or abdominal symptoms after fructose-containing meals, hereditary fructose intolerance is worth considering. HFI is a liver enzyme deficiency — Aldolase B — that causes the liver to accumulate fructose-1-phosphate, driving fat production, elevated triglycerides, and reactive hypoglycemia through a completely different mechanism than insulin resistance. The standard diabetes and metabolic syndrome workup does not test for it. See the HFI page in the Metabolic & Genetic section of the Medical Library.

If you have been told your triglycerides are elevated and your diabetes management isn't moving them the way it should — and especially if you have any history of aversion to sweet foods, fruit, or anything that would have contained fructose — that question is worth asking directly.

The NAFLD connection

Non-alcoholic fatty liver disease occurs at significantly elevated rates in people with Type 2 diabetes and insulin resistance. The liver's role in glucose and fat metabolism means that when insulin signaling is disrupted, fat accumulation in liver tissue is a common downstream consequence.

NAFLD and Type 2 are frequently found together, frequently worsen together, and share management strategies around dietary change and weight reduction.

What the standard workup does not routinely consider: NAFLD caused by hereditary fructose intolerance looks identical on imaging to NAFLD caused by insulin resistance. The liver does not label its fat by cause. If NAFLD is present alongside elevated triglycerides and reactive hypoglycemia — particularly in someone whose metabolic picture does not fully respond to standard interventions — the HFI page is worth reading carefully.

History

Type 2 diabetes has existed throughout recorded human history, described in ancient Egyptian, Indian, and Chinese medical texts — typically distinguished from what we now call Type 1 by the age of onset and the slower progression. The name "diabetes mellitus" — from the Greek for siphon and the Latin for honey — reflects the sweet urine that ancient physicians observed and the excessive urination that accompanied it.

The modern understanding of insulin resistance as the core mechanism of Type 2 developed across the twentieth century, with significant acceleration in the latter half as metabolic research matured. The epidemic expansion of Type 2 diagnoses in the latter decades of the twentieth century tracked closely with shifts in the food supply — specifically the widespread introduction of high-fructose corn syrup beginning in the mid-1970s and the dramatic increase in processed food consumption.

That correlation is not simple causation and the research is ongoing. But the timing is documented, the fructose-triglyceride connection is biochemically established, and the parallel rise in NAFLD, metabolic syndrome, and Type 2 diagnoses across the same period is not coincidental. The food system changed. The metabolic disease burden changed with it.

What you can do about it

Management of Type 2 involves addressing insulin resistance through a combination of dietary change, physical activity, medication when indicated, and monitoring.

Dietary approaches: Low carbohydrate and very low carbohydrate diets have shown meaningful benefit for blood glucose management and triglyceride reduction in Type 2. This is not a fringe position — it is documented in peer-reviewed literature and increasingly reflected in clinical guidelines. The mechanism is direct: reducing carbohydrate intake reduces the glucose load the insulin-resistant system has to manage.

Medications:

• Metformin — first-line oral medication, reduces hepatic glucose production

• GLP-1 receptor agonists — a class including semaglutide that reduces appetite, slows gastric emptying, and reduces blood glucose. Significant data on cardiovascular benefit.

• SGLT2 inhibitors — reduce glucose reabsorption in the kidneys, documented cardiovascular and renal protective effects

• Insulin — used when oral medications and other approaches are insufficient to maintain target glucose levels

Monitoring:

• HbA1c every 3 months until stable, then every 6 months

• Annual lipid panel

• Annual urine albumin-to-creatinine ratio — kidney monitoring

• Annual eye exam — diabetic retinopathy screening

• Annual foot exam — peripheral neuropathy monitoring

• Blood pressure monitoring

Asking for the right test

Type 2 diagnosis and monitoring involve a relatively standardized set of tests, but there are gaps worth knowing about.

For diagnosis and screening:

• Fasting blood glucose — 126 mg/dL or higher on two separate occasions indicates diabetes

• HbA1c — 6.5% or higher indicates diabetes; 5.7 to 6.4% indicates pre-diabetes

• Oral glucose tolerance test — two-hour glucose measurement after a standardized glucose load

For fuller metabolic picture:

• Fasting insulin level — not routinely ordered but can reveal insulin resistance before glucose rises into the diabetic range

• Full lipid panel including triglycerides

• Liver enzymes — ALT, AST — to assess NAFLD

• Uric acid — elevated in insulin resistance and metabolic syndrome

• Complete thyroid panel — TSH, Free T3, Free T4, TPO antibodies — thyroid dysfunction affects glucose metabolism and is frequently missed with TSH alone

What the standard workup does not include: The standard Type 2 workup does not include testing for hereditary fructose intolerance. It does not include Aldolase B enzyme activity. It does not include ALDOB gene sequencing. If the HFI triad — elevated triglycerides, NAFLD, reactive hypoglycemia — is present and the metabolic picture is not responding as expected, ask your physician specifically about HFI as a differential. See the HFI Testing page for the critical correction on what tests are and are not safe.

Personal note

Type 2 diabetes does not appear in my family history that I can trace on either side. I am documenting this page because Type 2 sits at the intersection of several things this library exists to flag — the fructose-triglyceride connection, the NAFLD overlap, the reactive hypoglycemia differential — and because the HFI misdiagnosis risk inside a metabolic syndrome workup is significant and almost entirely undiscussed.

Here is the piece that is personal: the timeline of the Type 2 epidemic tracks almost exactly with the timeline of high-fructose corn syrup deployment into the American food supply beginning in the mid-1970s. I was a child in that food system. My celiac and HFI were undiagnosed for decades while I was eating exactly what the food system was producing in increasing quantity. I am not saying HFCS caused my conditions. I am saying the food system changed in ways that were particularly harmful for people with the genetics I carry — and that millions of people in the same genetic position got the same exposure with no way to know what it was doing to them.

The reactive hypoglycemia I experienced for decades was attributed to blood sugar instability. It was actually HFI — a liver that could not process fructose, producing a metabolic crash every time fructose hit the system. The standard metabolic workup was not looking for that. It never is.

If your Type 2 picture doesn't fully add up — if the triglycerides won't move the way they should, if the reactive hypoglycemia doesn't fit the standard pattern, if you have any memory of avoiding sweet foods as a child without knowing why — the HFI page is worth reading before you accept that the standard workup has found everything there is to find.

I'm not a doctor. I'm not telling you to change your medication.

Sources

• CDC — National Diabetes Statistics Report — cdc.gov

• American Diabetes Association — Standards of Medical Care in Diabetes — diabetes.org

• Bray GA, Nielsen SJ, Popkin BM (2004) — Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. American Journal of Clinical Nutrition. PMID: 15051594 — PubMed

• Lustig RH (2010) — Fructose: metabolic, hedonic, and societal parallels with ethanol. Journal of the American Dietetic Association. PMID: 20696234 — PubMed

• Chalasani N, et al. (2018) — The diagnosis and management of nonalcoholic fatty liver disease. Hepatology. PMID: 28714183 — PubMed

• Westman EC, et al. (2008) — The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutrition & Metabolism. PMID: 18705670 — PubMed

• Maruthur NM, et al. (2016) — Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes. Annals of Internal Medicine. PMID: 27088241 — PubMed

• Loomba R, Sanyal AJ (2013) — The global NAFLD epidemic. Nature Reviews Gastroenterology & Hepatology. PMID: 23958599 — PubMed